Work

Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas

Year: 2026

Type: article

Study design: Clinical Trial

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.126.272007

Authors: Jialin Xiang, Xuejun Wen, Rongxi Wang, Jiarou Wang, Xingtong Peng, Yanwei Wang, Naixin Liang, Dongyan Cao, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, National University of Singapore, Shandong Tumor Hospital

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7203832481

FWCI:

Cites: 31

Cited by:

Related to: